Expert thinking on productivity, intangible asset valuation, growth strategy, and building more valuable businesses.
A practical framework for using intellectual property as loan collateral in the UK — which IP categories qualify, legal requirements, collateral suitability scoring, and common pitfalls.
Read more →
How IP-backed lending works in the UK — which assets qualify, valuation methods banks accept, typical loan terms, and how to prepare your application for IP finance.
Read more →
How IP valuations work for lending — four accepted methods, IVS compliance requirements, what banks actually need, common failures, and how to get lending-ready.
Read more →
SaaS businesses generate value through intangible assets that compound over time — customer relationships measured by ARR and retention, technology platforms that scale without proportional cost, and data assets that improve with usage. Understanding the intangible asset composition of a SaaS business changes how you value it.
Read more →
How to value trade names and trademarks using the Relief from Royalty method. Covers royalty rate selection for marketing-related intangibles, useful life considerations for brands, and the factors that distinguish a valuable trade name from a generic one.
Read more →A step-by-step guide to filing retroactive R&D expense claims under Section 174A of the OBBBA. Covers eligibility, the amended return process, Section 280C coordination, and practical examples of tax impact — all before the July 6, 2026 deadline.
Read more →
How to value internet domain names as intangible assets under IFRS 3. Covers valuation approaches, the strategic importance of premium domains, and recognition criteria in purchase price allocations.
Read more →
How intangible asset valuations are used for tax purposes, including tax amortisation benefits in acquisitions, transfer pricing for intercompany transactions, and the key differences between tax and financial reporting valuations.
Read more →
Pharmaceutical companies derive the vast majority of their value from intangible assets — drug patents, clinical trial data, regulatory approvals, and the pipeline of compounds in development. Valuing these assets requires specialised methods that account for the unique risk profile and regulatory pathway of drug development.
Read more →R&D spending creates intangible capital that rarely appears on the balance sheet. This article examines the gap between what companies invest in R&D and what their financial statements show, with practical guidance on mapping R&D to intangible asset categories under both US and UK accounting frameworks.
Read more →The One Big Beautiful Bill Act restored full R&D expensing under new Section 174A for tax years beginning 2025. Small businesses can retroactively reclaim deductions for 2022-2024. Here is what changed, who qualifies, and what the July 6 2026 deadline means for your company.
Read more →
Advanced manufacturing firms are routinely valued for their tangible assets — plant, machinery, inventory. But the process patents, proprietary manufacturing know-how, digital twin models, and engineering design IP that make those physical assets productive often exceed them in value. Structured lending against these intangibles can transform manufacturing finance.
Read more →Get the latest insights on intangible asset growth and productivity delivered to your inbox.
Take the free intangible asset assessment and discover where your biggest growth opportunities lie.